

SUPPLEMENTARY MATERIALS

Table S1. Level of Chromosomal instability (CIN), Clonal Heterogeneity (True Diversity Index) and Aneuploidy observed in luminal B BC patients.

RS	PAT	CHR	CIN %	CH TD index	ANE %
ER+/PR+/HER2-	B1	CEP2	43	3.3	63
		CEP3	48	3.4	63
		CEP8	66	4.7	44
		CEP11	17	1.7	82
		CEP15	40	2.4	85
		CEP17	49	2.7	80
		Total	44	3.0	70
	B2	CEP2	58	4.3	41
		CEP3	47	3.8	49
		CEP8	57	3.7	46
		CEP11	32	2.2	78
		CEP15	20	1.8	80
		CEP17	37	3.0	41
		Total	42	3.1	56
	B3	CEP2	50	4.2	52
		CEP3	42	3.3	50
		CEP8	43	3.2	58
		CEP11	34	2.3	82
		CEP15	37	2.3	81
		CEP17	42	2.3	90
		Total	41	2.9	69
	B4	CEP2	51	4.0	43
		CEP3	60	4.0	55
		CEP8	48	2.3	92
		CEP11	21	1.9	86
		CEP15	53	2.7	85
		CEP17	63	5.1	43
		Total	49	3.3	67
ER+/PR-/HER2-	B6	CEP2	60,61	4.1	51
		CEP3	49	4.5	39
		CEP8	62	4.3	48
		CEP11	30,3	2.2	69
		CEP15	15	1.6	80
		CEP17	67	3.8	46
		Total	47	3.4	56
	B8	CEP2	51	4.0	43

ER+/PR+/HER2+		CEP3	59	4.7	37
		CEP8	42	3.1	60
		CEP11	19	1.7	89
		CEP15	45	3.6	53
		CEP17	44	2.9	66
		Total	43	3.3	58
	B10	CEP2	40	2.5	80
		CEP3	39	3.0	46
		CEP8	46	3.1	50
		CEP11	21	1.9	71
		CEP15	30	2.3	70
		CEP17	21	1.9	57
		Total	33	2.5	62
	B5	CEP2	44	3.0	73
		CEP3	54	4.4	54
		CEP8	33	2.6	70
		CEP11	13	1.6	85
		CEP15	12	1.4	100
		CEP17	50	2.7	82
		Total	34	2.6	77
	B7	CEP2	38	2.9	47
		CEP3	58	4.4	43
		CEP8	62	4.4	48
		CEP11	32	2.2	84
		CEP15	64	3.9	52
		CEP17	56	3.5	64
		Total	52	3.5	56
	B9	CEP2	42	2.9	69
		CEP3	38	3.0	47
		CEP8	38	2.4	79
		CEP11	12	1.6	58
		CEP15	22	1.8	86
		CEP17	61	3.8	52
		Total	36	2.6	65

Notes: According to the CIN level (% CIN), each patient was classified as having low CIN (CIN=0-25%), intermediate CIN (CIN=26%-50%), high CIN (CIN=51%-70%), or extreme CIN (CIN>70%). Stable or unstable aneuploidy was determined for each chromosome. A chromosome was considered to have stable aneuploidy if more than 20% (>20%) of the cells have identical probe signal patterns, while a chromosome, with fewer than 20% (<20%) of the cells with identical probe signal patterns was considered to have unstable aneuploidy. **Abbreviations:** RS, Receptor Status; PAT, Patient; CHR, Chromosome; CIN, Chromosomal Instability; ANE, Aneuploidy.

Table S2. CEP copy number variation (gains and losses) observed in luminal B BC patients.

RS	PAT	CHR	% CNV	TOTAL CNV
ER+/PR+/HER2-	B1	CEP2	1.77	1.17
		CEP3	1.53	
		CEP8	1.41	
		CEP11	0.2	
		CEP15	0.47	
		CEP17	1.65	
	B2	CEP2	1.47	0.93
		CEP3	1.54	
		CEP8	1.22	
		CEP11	0.39	
		CEP15	0.24	
		CEP17	0.69	
	B3	CEP2	2.01	1.14
		CEP3	1.58	
		CEP8	0.76	
		CEP11	0.43	
		CEP15	0.45	
		CEP17	1.6	
	B4	CEP2	1.5	1.78
		CEP3	2.46	
		CEP8	1.55	
		CEP11	0.25	
		CEP15	1.66	
		CEP17	3.27	
ER+/PR-/HER2-	B6	CEP2	1.54	1.15
		CEP3	2.08	
		CEP8	1.51	
		CEP11	0.39	
		CEP15	0.18	
		CEP17	1.21	
	B8	CEP2	1.75	1.09
		CEP3	1.61	
		CEP8	0.7	
		CEP11	0.21	
		CEP15	0.87	
		CEP17	1.38	
	B10	CEP2	1.33	0.82
		CEP3	1.37	

ER+/PR+/HER2+		CEP8	1.27	0.93
		CEP11	0.27	
		CEP15	0.4	
		CEP17	0.3	
	B5	CEP2	1.49	
		CEP3	1.93	
		CEP8	0.5	
		CEP11	0.15	
		CEP15	0.12	
		CEP17	1.41	
	B7	CEP2	1.1	
		CEP3	1.56	
		CEP8	1.65	
		CEP11	0.38	
		CEP15	1.41	
		CEP17	1.57	
	B9	CEP2	1.33	
		CEP3	1.23	
		CEP8	0.47	
		CEP11	0.17	
		CEP15	0.25	
		CEP17	1.55	

Notes: CEP2, CEP3, CEP8, CEP11, CEP15 and CEP17 copy number variations (gains and losses) were evaluated in all cases. According to the criteria for CEP copy number gain (mean CEP count ≥ 3) and loss (mean CEP count < 1.6). **Abbreviations:** RS, Receptor Status; PAT, Patients; CHR, Chromosome; CNV, Copy number variation

SUPPLEMENTARY FIGURE S1 CAPTION

Figure S1. Multivariate analysis with Pearson correlation coefficient between clonal heterogeneity (CH) and clinicopathologic characteristics. Values greater than 0.5 are indicative of a statistically significant correlation. No correlation was found between CH with any of the variables studied: histotype (HT), tumor size (T), lymph nodes (N), lymphovascular invasion (LI), progesterone receptor (PR), HER2 and KI67.